# Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/cardiology/strokes/123815) · 2026-11-10 · Medicine
Page: https://themorning.science/story/next-gen-anticoagulant-lands-fda-nod-for-secondary-stroke-prevention-75508ce731af0bfe
Kind: release · Impact: medium

## In brief

- The FDA approved asundexian (brand name Sunharbo) for secondary stroke prevention.
- Asundexian is described as the first factor XIa (FXIa) inhibitor approved for this use.
- It is an oral, direct, small-molecule FXIa inhibitor.

## Why it matters

It adds a new oral anticoagulant class for preventing recurrent stroke, which science and medical readers may track as an alternative to existing antithrombotic drugs.

## Timeline

- 2026-11-10: FDA announced approval of asundexian (Sunharbo) for secondary stroke prevention

## Coverage

- [Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention](https://www.medpagetoday.com/cardiology/strokes/123815) — MedPageToday.com - medical news for physicians, 2026-11-10

Tags: stroke prevention, anticoagulants, factor xi inhibitor, fda approval, asundexian

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science